Johnson, Patrick Stephen,Dack, Kevin Neil,Henriksson, Krister
申请号：
HRP20200130
公开号：
HRP20200130T1
申请日:
2020.01.27
申请国别(地区):
HR
年份:
2020
代理人:
摘要：
wherein R1 is selected from the group consisting of 5- and 6-membered heteroaryl, (C1-C6)alkyl, (C3-C6)cycloalkyl, (4-6)-membered heterocycloalkyl and phenyl； R2 is selected from (C1-C3)alkyl and halo(C1-C3)alkyl； R3 is selected from phenyl, 5-membered heteroaryl and 6-membered heteroaryl； R4 is selected from hydrogen, halogen, (C1-C4)alkyl and halo(C1-C4)alkyl； X1 is selected from CH, C(Rb) and N, X2 is selected from CH and N； Y is selected from —NH— and —O—； m is 0 or 1； n is 0 or 1； L represents a bond, —O—, —NH— or —N(Rc)—； or pharmaceutically acceptable salts, hydrates, or solvates thereof. The invention relates further to intermediates for the preparation of said compounds, to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases with said compounds, and to the use of said compounds in the manufacture of medicaments.
